Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Aug 24;2015(8):CD007577.
doi: 10.1002/14651858.CD007577.pub3.

Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults

Richard Pugh  1 , Chris Grant, Richard P D Cooke, Ged Dempsey
Affiliations
Meta-Analysis

Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults

Richard Pugh et al. Cochrane Database Syst Rev. .

Abstract

Background: Pneumonia is the most common hospital-acquired infection affecting patients in the intensive care unit (ICU). However, current national guidelines for the treatment of hospital-acquired pneumonia (HAP) are several years old and the diagnosis of pneumonia in mechanically ventilated patients (VAP) has been subject to considerable recent attention. The optimal duration of antibiotic therapy for HAP in the critically ill is uncertain.

Objectives: To assess the effectiveness of short versus prolonged-course antibiotics for HAP in critically ill adults, including patients with VAP.

Search methods: We searched CENTRAL (2015, Issue 5), MEDLINE (1946 to June 2015), MEDLINE in-process and other non-indexed citations (5 June 2015), EMBASE (2010 to June 2015), LILACS (1982 to June 2015) and Web of Science (1955 to June 2015).

Selection criteria: We considered all randomised controlled trials (RCTs) comparing a fixed 'short' duration of antibiotic therapy with a 'prolonged' course for HAP (including patients with VAP) in critically ill adults.

Data collection and analysis: Two review authors conducted data extraction and assessment of risk of bias. We contacted trial authors for additional information.

Main results: We identified six relevant studies involving 1088 participants. This included two new studies published after the date of our previous review (2011). There was substantial variation in participants, in the diagnostic criteria used to define an episode of pneumonia, in the interventions and in the reported outcomes. We found no evidence relating to patients with a high probability of HAP who were not mechanically ventilated. For patients with VAP, overall a short seven- or eight-day course of antibiotics compared with a prolonged 10- to 15-day course increased 28-day antibiotic-free days (two studies; N = 431; mean difference (MD) 4.02 days; 95% confidence interval (CI) 2.26 to 5.78) and reduced recurrence of VAP due to multi-resistant organisms (one study; N = 110; odds ratio (OR) 0.44; 95% CI 0.21 to 0.95), without adversely affecting mortality and other recurrence outcomes. However, for cases of VAP specifically due to non-fermenting Gram-negative bacilli (NF-GNB), recurrence was greater after short-course therapy (two studies, N = 176; OR 2.18; 95% CI 1.14 to 4.16), though mortality outcomes were not significantly different. One study found that a three-day course of antibiotic therapy for patients with suspected HAP but a low Clinical Pulmonary Infection Score (CPIS) was associated with a significantly lower risk of superinfection or emergence of antimicrobial resistance, compared with standard (prolonged) course therapy.

Authors' conclusions: On the basis of a small number of studies and appreciating the lack of uniform definition of pneumonia, we conclude that for patients with VAP not due to NF-GNB a short, fixed course (seven or eight days) of antibiotic therapy appears not to increase the risk of adverse clinical outcomes, and may reduce the emergence of resistant organisms, compared with a prolonged course (10 to 15 days). However, for patients with VAP due to NF-GNB, there appears to be a higher risk of recurrence following short-course therapy. These findings do not differ from those of our previous review and are broadly consistent with current guidelines. There are few data from RCTs comparing durations of therapy in non-ventilated patients with HAP, but on the basis of a single study, short-course (three-day) therapy for HAP appears not to be associated with worse clinical outcome, and may reduce the risk of subsequent infection or the emergence of resistant organisms when there is low probability of pneumonia according to the CPIS.

PubMed Disclaimer

Conflict of interest statement

There were no sources of funding for this review.

Richard Pugh: none known. Chris Grant: none known. Richard PD Cooke: none known. Ged Dempsey: none known.

Figures

1
1
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Capellier 2012 {published data only}
    1. Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T, et al. Early‐onset ventilator‐associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PloS One 2012;7(8):e41290. - PMC - PubMed
Chastre 2003a {published data only}
    1. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator‐associated pneumonia in adults: a randomized trial. JAMA 2003;290(19):2588‐98. - PubMed
Fekih Hassen 2009 {published data only}
    1. Fekih Hassen M, Ayed S, Ben Sik Ali H, Gharbi R, Marghli S, Elatrous S. Duration of antibiotic therapy for ventilator‐associated pneumonia: comparison of 7 and 10 days. A pilot study. Annales Françaises d'Anesthésie et de Réanimation 2009;28(1):16‐23. - PubMed
Kollef 2012 {published data only}
    1. Kollef M, Chastre J, Restrepo M, Michiels B, Kaniga K, Cirillo I, et al. A randomized trial of 7‐day doripenem versus 10‐day imipenem‐cilastatin for ventilator‐associated pneumonia. Critical Care 2012;16:R218. - PMC - PubMed
Medina 2007 {published and unpublished data}
    1. Medina JC, Perez Protto SE, Paciel D, Pontet J, Saldun P, Berro M. Antibiotic treatment for the ventilator‐associated pneumonia: 8 vs. 12 days randomized trial preliminary data. Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. 2007.
Singh 2000 {published data only}
    1. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short‐course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. American Journal of Respiratory and Critical Care Medicine 2000;162:505‐11. - PubMed

References to studies excluded from this review

Bouadma 2010 {published data only}
    1. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375(9713):463‐74. - PubMed
Cai 2001 {published data only}
    1. Cai S, Zhang J, Qian G. Impact of quantitative and qualitative pathogen culture on the outcome of ventilator‐associated pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2001;24(8):494‐7. - PubMed
CCCTG 2006 {published data only}
    1. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator‐associated pneumonia. New England Journal of Medicine 2006;355(25):2619‐30. - PubMed
Chastre 2003b {published data only}
    1. Chastre J, Wolff M, Fagon JY, Chevret S. Comparison of two durations of antibiotic therapy to treat ventilator‐associated pneumonia (VAP). American Thoracic Society Meeting, Seattle, Washington. 2003:A015.
Fagon 2000 {published data only}
    1. Fagon JY, Chastre J, Wolff M, Gervais C, Parer‐Aubas S, Stéphan F, et al. Invasive and noninvasive strategies for management of suspected ventilator‐associated pneumonia. A randomized trial. Annals of Internal Medicine 2000;132(8):621‐30. - PubMed
Hochreiter 2009 {published data only (unpublished sought but not used)}
    1. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009;13(3):R83. - PMC - PubMed
Ibrahim 2001 {published data only}
    1. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator‐associated pneumonia. Critical Care Medicine 2001;29(6):1109‐15. - PubMed
Kim 2009 {published data only}
    1. Kim JW, Chung J, Jang HJ, Hong SB, Lim CM, Koh Y. De‐escalation of antibiotics in critically ill patients with hospital‐acquired pneumonia. Respirology. 2009; Vol. 14:A129.
Kim 2012 {published data only}
    1. Kim JW, Chung J, Choi SH, Jang HJ, Hong SB, Lim CM, et al. Early use of imipenem/cilastatin and vancomycin followed by de‐escalation versus conventional antimicrobials without de‐escalation for patients with hospital‐acquired pneumonia in a medical ICU: a randomized clinical trial. Critical Care 2012;16(1):R28. - PMC - PubMed
Kollef 2005 {published data only}
    1. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator‐associated pneumonia and negative quantitative BAL culture results. Chest 2005;128:2706‐13. - PubMed
Labelle 2012 {unpublished data only}
    1. Labelle AJ, Schoenberg N, Skrupky L, Kollef M. Five versus seven day antibiotic course for the treatment of pneumonia in the intensive care unit. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6078.
Maldonado‐Ortiz 2004 {unpublished data only}
    1. Maldonado‐Ortiz EA, Niederman MS, Nacul F, Rodríguez A, Ceballos S, Osorio J. How long is enough to treat ventilator associated pneumonia? A randomized pilot study: the Latinoamerican experience. Chest 2004;126(Suppl 4):717.
Micek 2004 {published data only}
    1. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator‐associated pneumonia. Chest 2004;125(5):1791‐9. - PubMed
Nobre 2008 {published data only}
    1. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2008;177(5):498‐505. - PubMed
Peery 2001 {published data only}
    1. Peery C, Chendrasekhar A, Moorman DW, Timberlake GA. Ventilator‐associated pneumonia therapy: protected specimen brushing versus tracheal aspirate data. Journal of Applied Research 2001;1(2):1.
Pontet 2007 {published and unpublished data}
    1. Pontet J, Paciel D, Olivera W, Bentancourt S, Cancela M, Gervas J. Procalcitonin (PCT) guided antibiotic treatment in ventilator associated pneumonia (VAP). Multi‐centre, clinical prospective, randomized‐controlled study. American Thoracic Society International Conference, San Francisco, California, USA. 2007:A76.
Rello 2004 {published data only}
    1. Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, et al. De‐escalation therapy in ventilator‐associated pneumonia. Critical Care Medicine 2004;32(11):2183‐90. - PubMed
Sanchez‐Nieto 1998 {published data only}
    1. Sanchez‐Nieto JM, Torres A, Garcia‐Cordoba F, El‐Ebiary M, Carrillo A, Ruiz J, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator‐associated pneumonia: a pilot study. American Journal of Respiratory and Critical Care Medicine 1998;157(2):371‐6. - PubMed
Schroeder 2007 {published data only (unpublished sought but not used)}
    1. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)‐guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's Archives of Surgery 2009;394:221‐6. - PubMed
Singh 1998 {published data only}
    1. Singh N. Short‐course empiric antibiotic therapy for suspected nosocomial pneumonia: a proposed solution for indiscriminate antibiotic prescription for pulmonary infiltrates in the ICU. Annual Meeting of the Infectious Disease Society of America, Denver, Colorado. 1998.
Sole 2000 {published data only}
    1. Sole VJ, Fernandez JA, Benitez AB, Cardenosa Cendrero JA, Rodriguez de CF. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Critical Care Medicine 2000;28(8):2737‐41. - PubMed
Stolz 2009a {published and unpublished data}
    1. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator‐associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364‐75. - PubMed
Stolz 2009b {published data only}
    1. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for antibiotic de‐escalation in ventilator associated pneumonia ‐ a randomized study. European Respiratory Society Annual Congress, Vienna. 2009:2798. - PubMed
Svoboda 2007 {published data only}
    1. Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re‐intervention in septic patients after multiple trauma or major surgery?. Hepatogastroenterology 2007;54:359‐63. - PubMed
Wolff 2003 {published data only}
    1. Wolff M, Chastre J, Fagon JY, Chevret S. Comparison of two durations of antibiotic therapy for ventilator‐associated pneumonia (VAP) caused by non‐fermenting gram negative bacilli (NF‐GNB). American Thoracic Society Meeting Seattle, Washington. 2003:A860.

References to ongoing studies

NCT00410527 {published data only}
    1. Effectiveness of short‐course versus standard antibiotic therapy in ICU patients. http://clinicaltrials.gov/ct2/show/study/NCT00410527 2006 (accessed 5 June, 2015).
NCT01554657 {published data only}
    1. Five versus seven day antibiotic course for the treatment of pneumonia in the intensive care unit. https://clinicaltrials.gov/show/NCT01554657 2012 (accessed 5 June, 2015).
NCT01994980 {published data only}
    1. Duration of antibiotic treatment for early VAP. http://clinicaltrials.gov/show/NCT01994980 2013 (accessed 5 June, 2015).

Additional references

Agrafiotis 2010
    1. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator‐associated tracheobronchitis: systematic review and meta‐analysis. Respiratory Medicine 2010;104:325‐36. - PubMed
ATS/IDSA 2005
    1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital‐acquired, ventilator‐associated, and healthcare‐associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005;171(4):388‐416. - PubMed
Bekaert 2011
    1. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste‐Orgeas M, et al. Attributable mortality of ventilator‐associated pneumonia: a reappraisal using causal analysis. American Journal of Respiratory and Critical Care Medicine 2011;184(10):133‐9. - PubMed
Bignardi 1998
    1. Bignardi GE. Risk factors for Clostridium difficile infection. Journal of Hospital Infection 1998;40(1):1‐15. - PubMed
Blot 2013
    1. Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA, et al. Prevalence, risk factors, and mortality for ventilator‐associated pneumonia in middle‐aged, old, and very old critically ill patients. Critical Care Medicine 2014;42:601‐9. - PubMed
Boyer 2015
    1. Boyer AF, Schoenberg N, Babcock H, McMullen KM, Micek ST, Kollef MH. A prospective evaluation of ventilator‐associated conditions and infection‐related ventilator‐associated conditions. Chest 2015;147:68‐81. - PubMed
BSAC 2008
    1. Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, et al. Guidelines for the management of hospital‐acquired pneumonia in the UK: report of the working party on hospital‐acquired pneumonia of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy 2008;62(1):5‐34. - PMC - PubMed
Burgmann 2010
    1. Burgmann H, Hiesmayer J, Savey A, Bauer P, Metnitz B, Metnitz P. Impact of nosocomial infections on clinical outcome and resource consumption in critically ill patients. Intensive Care Medicine 2010;36:1597‐601. - PubMed
Chant 2012
    1. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta‐analysis. Critical Care 2012;17:R279. - PMC - PubMed
Chastre 2002
    1. Chastre J, Fagon JY. Ventilator‐associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2002;165:867‐903. - PubMed
Combes 2007
    1. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Early predictors for infection recurrence and death in patients with ventilator‐associated pneumonia. Critical Care Medicine 2007;35(1):146‐54. - PubMed
Conway Morris 2011
    1. Morris AC, Kefala K, Simpson AJ, Wilkinson TS, Everingham K, Kerslake D, et al. Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator‐associated pneumonia. Thorax 2011;64:516‐22. - PubMed
Dallas 2011
    1. Dallas J, Skrupky L, Abebe N, Boyle W, Kollef M. Ventilator‐associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011;139:513‐8. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Dennesen 2001
    1. Dennesen PJ, Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator‐associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2001;163(6):1371‐5. - PubMed
Dimopoulos 2013
    1. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short‐ versus long‐duration antibiotic regimens for ventilator‐associated pneumonia: a systematic review and meta‐analysis. Chest 2013;144:1759‐67. - PubMed
Dubberke 2014
    1. Dubberke E, Carling P, Carrico R, Donskey C, Loo V, McDonald L, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infection Control and Hospital Epidemiology 2014;35:628‐45. - PubMed
Dugan 2003
    1. Dugan HA, MacLaren R, Jung R. Duration of antimicrobial therapy for nosocomial pneumonia: possible strategies for minimizing antimicrobial use in intensive care units. Journal of Clinical Pharmacy and Therapeutics 2003;28(2):123‐9. - PubMed
El Solh 2007
    1. Solh AA, Choi G, Schultz MJ, Pineda LA, Mankowski C. Clinical and hemostatic responses to treatment in ventilator‐associated pneumonia: role of bacterial pathogens. Critical Care Medicine 2007;35(2):490‐6. - PubMed
Esperatti 2010
    1. Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo L, et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. American Journal of Respiratory and Critical Care Medicine 2010;182:1533‐9. - PubMed
FDA 2014
    1. US Food, Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. FDA Drug Safety Communication 2014:http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm (accessed 4 May 2015).
Gastmeier 2009
    1. Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg R, Welte T. Early‐ and late‐onset pneumonia: is this still a useful classification?. Antimicrobial Agents and Chemotherapy 2009;53:2714‐8. - PMC - PubMed
Grammatikos 2008
    1. Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator‐acquired pneumonia. Expert Review of Anti‐infective Therapy 2008;6(6):861‐6. - PubMed
Hayashi 2013
    1. Hayashi Y, Morisawa K, Klompas M, Jones M, Bandeshe H, Boots R, et al. Toward improved surveillance: the impact of ventilator‐associated complications on length of stay and antibiotic use in patients in intensive care units. Clinical Infectious Disease 2013;56:471‐7. - PubMed
HELICS 2004
    1. Hospital in Europe Link for Infection Control through Surveillance (HELICS). Surveillance of Nosocomial infections in intensive care units, Protocol Version 6.1. http://ecdc.europa.eu/en/activities/surveillance/HAI/Documents/0409_IPSE... 2004 (accessed 9 January 2015).
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed
Horan 2008
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care‐associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008;36:309‐32. - PubMed
Jensen 2011
    1. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin‐guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39:2048‐58. - PubMed
Kipnis 2014
    1. Kipnis E, Nseir S. Ventilator‐associated events (VAEs): VAE Victis? (Woe to the conquered?)*. Critical Care Medicine 2014;42(8):1949‐50. - PubMed
Klein Klouwenberg 2014
    1. Klein Klouwenberg P, Mourik M, Ong D, Horn J, Schultz M, Cremer O, et al. Electronic implementation of a novel surveillance paradigm for ventilator‐associated events. Feasibility and validation. American Journal of Respiratory and Critical Care Medicine 2014;189:947‐55. - PubMed
Kohlenberg 2010
    1. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. Intensive Care Medicine 2010;36(6):971‐8. - PubMed
Kollef 1995
    1. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late‐onset ventilator‐associated pneumonia in determining patient mortality. Chest 1995;108(6):1655‐62. - PubMed
Kollef 2012b
    1. Kollef MH, Micek ST. Antimicrobial stewardship programs: mandatory for all ICUs. Critical Care 2012;16(6):179. - PMC - PubMed
Kopterides 2010
    1. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin‐guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta‐analysis of randomized controlled trials. Critical Care Medicine 2010;38(11):2229‐41. - PubMed
Koulenti 2009
    1. Koulenti D, Lisboa T, Brun‐Buisson C, Krueger W, Macor A, Sole‐Violan J, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine 2009;37:2360‐8. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6. Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Luna 2003
    1. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, et al. Resolution of ventilator‐associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Critical Care Medicine 2003;31(3):676‐82. - PubMed
Magill 2013
    1. Magill S, Klompas M, Balk R, Burns SM, Deutschman C, Diekema D, et al. Developing a new, national approach to surveillance for ventilator‐associated events. Critical Care Medicine 2013;41:2467‐75. - PMC - PubMed
Martin‐Loeches 2015
    1. Martin‐Loeches I, Torres A, Rinaudo M, Terraneo S, Rosa F, Ramirez P, et al. Resistance patterns and outcomes in intensive care unit (ICU)‐acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. Journal of Infection 2015;70:213‐22. - PubMed
Melsen 2011
    1. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator‐associated pneumonia from randomized prevention studies. Critical Care Medicine 2011;39(12):2736‐42. - PubMed
Melsen 2013
    1. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator‐associated pneumonia: a meta‐analysis of individual patient data from randomised prevention studies. Lancet Infectious Diseases 2013;13(8):665‐71. - PubMed
Mueller 2007
    1. Mueller EW, Croce MA, Boucher BA, Hanes SD, Wood GC, Swanson JM, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator‐associated pneumonia. Journal of Trauma 2007;63(6):1329‐37. - PubMed
Muscedere 2013
    1. Muscedere J, Sinuff T, Heyland D, Dodek P, Keenan S, Wood G, et al. The clinical impact and preventability of ventilator‐associated conditions in critically ill patients who are mechanically ventilated. Chest 2013;144:1453‐60. - PubMed
Niederman 2012
    1. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41‐6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram‐negative pneumonia. Intensive Care Medicine 2012;38:263‐71. - PubMed
Rello 2002
    1. Rello J, Ollendorf DA, Oster G, Vera‐Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator‐associated pneumonia in a large US database. Chest 2002;122:2115‐21. - PubMed
Restrepo 2013
    1. Restrepo M, Peterson J, Fernandez J, Qin Z, Fisher A, Nicholson S. Comparison of the bacterial etiology of early‐onset and late‐onset ventilator‐associated pneumonia in subjects enrolled in 2 large clinical studies. Respiratory Care 2013;58:1220‐5. - PMC - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Richards 2000
    1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical‐surgical intensive care units in the United States. Infection Control and Hospital Epidemiology 2000;21(8):510‐5. - PubMed
Rotstein 2008
    1. Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, et al. Clinical practice guidelines for hospital‐acquired pneumonia and ventilator‐associated pneumonia in adults. Canadian Journal of Infectious Diseases and Medical Microbiology 2008;19(1):19‐53. - PMC - PubMed
Safdar 2005
    1. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator‐associated pneumonia: a systematic review. Critical Care Medicine 2005;33:2184‐93. - PubMed
Schuetz 2012a
    1. Schuetz P, Briel M, Christ‐Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta‐analysis. Clinical Infectious Diseases 2012;55:651‐62. - PMC - PubMed
Schuetz 2012b
    1. Schuetz P, Müller B, Christ‐Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2] - DOI - PMC - PubMed
Sharpe 2015
    1. Sharpe JP, Magnotti LJ, Weinberg JA, Swanson JM, Schroeppel TJ, Clement LP, et al. Adherence to an established diagnostic threshold for ventilator‐associated pneumonia contributes to low false‐negative rates in trauma patients. Journal of Trauma and Acute Care Surgery 2015;78(3):468‐73. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Stoeppel 2014
    1. Stoeppel CM, Eriksson EA, Hawkins K, Eastman A, Wolf S, Minei J, et al. Applicability of the National Healthcare Safety Network's surveillance definition of ventilator‐associated events in the surgical intensive care unit: a 1‐year review. Journal of Trauma and Acute Care Surgery 2014;77:934‐7. - PubMed
Szakmany 2013
    1. Szakmany T, Harrison W, Roberts H, Scholey G, Pugh R. Surveillance for ventilator‐associated pneumonia (VAP) in Wales: is HELICS the best way?. Critical Care Medicine 2013;41(Suppl 12):46.
Vincent 1995
    1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas‐Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274(8):639‐44. - PubMed
Vincent 2009
    1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323‐9. - PubMed
Visscher 2008
    1. Visscher S, Schurink CA, Melsen WG, Lucas PJ, Bonten MJ. Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Intensive Care Medicine 2008;34(4):692‐9. - PubMed
Warren 2003
    1. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, et al. Outcome and attributable cost of ventilator‐associated pneumonia among intensive care unit patients in a suburban medical center. Critical Care Medicine 2003;31:1312‐7. - PubMed
Wunderink 2000
    1. Wunderink R. Radiologic diagnosis of ventilator‐associated pneumonia. Chest 117;117(Suppl):188‐90. - PubMed
Zhuo 2008
    1. Zhuo H, Yang K, Lynch SV, Dotson RH, Glidden DV, Singh G, et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Critical Care Medicine 2008;36(9):2495‐503. - PubMed

References to other published versions of this review

Pugh 2009
    1. Pugh R, Grant C, Cooke RPD, Dempsey G. Short‐course versus prolonged‐course antibiotic therapy for hospital‐acquired pneumonia in critically ill adults. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007577] - DOI
Pugh 2011
    1. Pugh R, Grant C, Cooke RPD, Dempsey G. Short‐course versus prolonged‐course antibiotic therapy for hospital‐acquired pneumonia in critically ill adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD007577.pub2] - DOI - PubMed

MeSH terms

Substances